Diprivan Articles

Teva and Baxter to pay $500 million in punitive damages, Nevada court rules; Teva settles with Watson

10 May 2010

India’s Piramal to buy Bharat Serums injectable anesthetics business

26 April 2010

CyDex Pharma IP to be auctioned

8 April 2009

Abraxis completes purchase of AstraZeneca brands

3 July 2006

AstraZeneca and Abraxis sign US Abraxane co-promotion deal for $200M

8 May 2006

SkyePharma ends Propofol deal with Endo

1 May 2006

Baxter launches sevoflurane in China

19 December 2005

UPDATE: MGI Pharma makes $178M bid for Guilford, plus assuming $69.4M convertible debt

1 August 2005

Guilford announces positive results for sedative injection

11 April 2005

Manhattan Pharma buys Tarpan

11 April 2005

Guilford completes sale and leaseback for $19.4M in net proceeds

10 January 2005

Manhattan Pharma to merge with Tarpan

10 January 2005

UPDATE: Guilford to acquire ProQuest for $7M

13 December 2004

SkyePharma gets $5M milestone from Endo for Propofol IDD-D

19 April 2004

SkyePharma issues full-year profit warning; unsteady revenues still to blame

29 September 2003

SkyePharma present new data on DepoMorphine and Propofol IDD-D

16 June 2003

SkyePharma swings to profit in 2002; forecasts increased growth this year

7 April 2003

Return to form for life sciences in 2003 after "dismal" 2002, say analysts

17 February 2003

SkyePharma licenses key drugs to Endo

13 January 2003

Baxter acquires ESI in $305M deal

6 January 2003

Guilford starts trial of propofol product

10 June 2002

Solid set of results at AstraZeneca, but Crestor approval delay

6 May 2002

Guilford sees Gliadel unit sales up 42%

25 February 2002

Solid set of results at AstraZeneca as Nexium continues to perform well

4 February 2002

AstraZeneca highlights key product growth over the next five years

6 December 2001

Solid results for AstraZeneca as Nexium continues to capture market share

24 October 2001

FH Faulding half-year profits up 35%

28 September 2001

Faulding sales rise 17.5%, boosted by pharma

9 August 2001

AstraZeneca hit by slip in Losec sales

26 April 2001

AstraZeneca issues sales and profits slowdown warning

8 February 2001

Two Guilford drugs near trials

14 December 2000

AstraZeneca rapped over Diprivan claims

14 September 2000

AstraZeneca updates on anesthetics

8 June 2000

Gensia Sicor gets court backing for propofol

16 August 1999

Positive 1st-qtr news from AstraZeneca

26 May 1999

Zeneca seeks injunction over generic propofol

21 April 1999

Zeneca loses bid to block generic propofol

30 March 1999

Diprivan use expanded in Japan

17 March 1999

Zeneca consolidates Thai business

9 March 1999

Zeneca shows confidence on Astra merger; reports good 1998 results

17 February 1999

Zeneca files lawsuit against FDA over Gensia Sicor's generic propofol

10 February 1999

US FDA feels growing pressure from industry, interest groups, over generics

9 February 1999

Gensia plans generic propofol launch in '99

13 January 1999

Abbott seeks approval for new sedative

12 January 1999

Chirocaine Approved In First Market

16 December 1998

Advances In CNS Therapeutics Reviewed By Lehman Analysts

30 November 1998

Zeneca Diprivan Patent Extension, New Zestril Indication

5 February 1998

Broker Upgrades Zeneca On Acquisition And New Product Outlook

13 January 1998

Zeneca Allays Fears Of Near-Term Product Gap

4 December 1997

Zeneca Sees Strong Growth Against The Odds

8 August 1997

Zeneca Breaks Records In 1996 As New Products Are Launched

17 March 1997

Strong Fundamentals On Show At Zeneca

19 August 1996

"Excellent" 1st Half For Zeneca But Share Price Falls

12 August 1996

Independent Position To Be Maintained At Zeneca

18 March 1996

Zeneca Takes Charge, But Still At Forecasts' Top-End

29 January 1996

Zeneca: Diprivan news

4 December 1995

Zeneca's Diprivan linked to postsurgical infection

31 July 1995

Good Performance Forecast For Euro Drugmakers

26 June 1995

Abbott's Ultane Approved In USA

19 June 1995

Disease ManagementThe Way Forward

15 May 1995

US Difficulties For Zeneca In 1994

6 March 1995

Abbott Files NDA For Sevorane Anesthetic

28 November 1994

Diprivan Gains New Indication In USA

7 November 1994

New Production Unit For Zeneca In Italy

10 October 1994

Zestril Launched In China

22 August 1994

Zeneca Praises 1st Half Underlying Growth

8 August 1994

ZENECA GETS ANALYST UPGRADING

11 July 1994

ZENECA PLANS CHINESE VENTURES

4 July 1994

ZENECA LICENSES DRUGS TO VHA INC

13 June 1994

ZENECA'S PIPELINE ON TARGET AS TENORMIN SLIPS

14 March 1994

"SUCCESS" IN FIRST YEAR FOR ZENECA

7 March 1994

BETTER SECOND HALF FOR ZENECA

31 January 1994

ZENECA DEVELOPING CHINESE BUSINESS

24 January 1994

DIPRIVAN GAINS NEW INDICATION IN USA

15 November 1993

ZENECA PROMOTION

1 November 1993

ZENECA/BURROUGHS WELLCOME DEAL

27 September 1993

ZENECA SURPRISES WITH STRONG PHARMA GROWTH

9 August 1993

ZENECA MAKES GOOD ADVANCES IN 1st HALF

2 August 1993

705p PRICE SET FOR ZENECA AS 1st QTR PROFITS RISE

3 May 1993

FDA CLEARS ZENECA'S ITALIAN PLANT

26 April 1993

DIPRIVAN APPROVED IN US FOR NEW INDICATION

22 March 1993

DIPRIVAN INDICATION EXTENDED IN USA

15 March 1993

TENORMIN DRAGS DOWN ZENECA AS IT DEMERGES

8 March 1993

ZENECA LAUNCH

18 January 1993

ICI AT "BREAKING POINT" WITH DEMERGER

14 December 1992

ZENECA'S PROMISING R&D PIPELINE PRESENTED

14 December 1992

DIPRIVAN LICENSED FOR ICU SEDATION

29 June 1992

ICI HONORED FOR DIPRIVAN ADVANCE

20 April 1992

Showing 1-88 of 88 articles

Go to beginningPrevious
  • 1
NextGo to end